Cargando…

Erythrodermic Psoriasis Causing Uric Acid Crystal Nephropathy

BACKGROUND: Erythrodermic psoriasis is a rare and severe variant of psoriasis. It is characterized by widespread skin erythema, scaling, pustules, or exfoliation of more than 75% of the body's surface area. This condition has life-threatening complications to include hemodynamic, metabolic, imm...

Descripción completa

Detalles Bibliográficos
Autores principales: Ellis, John, Lew, Jeffrey, Brahmbhatt, Sumir, Gordon, Sarah, Denunzio, Troy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458895/
https://www.ncbi.nlm.nih.gov/pubmed/31031815
http://dx.doi.org/10.1155/2019/8165808
_version_ 1783410108329361408
author Ellis, John
Lew, Jeffrey
Brahmbhatt, Sumir
Gordon, Sarah
Denunzio, Troy
author_facet Ellis, John
Lew, Jeffrey
Brahmbhatt, Sumir
Gordon, Sarah
Denunzio, Troy
author_sort Ellis, John
collection PubMed
description BACKGROUND: Erythrodermic psoriasis is a rare and severe variant of psoriasis. It is characterized by widespread skin erythema, scaling, pustules, or exfoliation of more than 75% of the body's surface area. This condition has life-threatening complications to include hemodynamic, metabolic, immunologic, and thermoregulatory disturbances. One metabolic complication, hyperuricemia, occurs from rapid keratinocyte differentiation and infiltration of inflammatory cells into psoriatic lesions. Although renal injury caused by shunting of blood to the skin has been reported, there are no reports of erythrodermic psoriasis causing crystal-induced nephropathy. We present a case of erythrodermic psoriasis and hyperuricemia complicated by uric acid crystal nephropathy. CASE PRESENTATION: A 57-year-old male with long-standing psoriatic arthritis presented with diffuse scaling of his skin. He was being treated with adalimumab, leflunomide, and topical clobetasol, but had recently stopped taking his medications. Physical exam revealed yellow scaling covering his entire body with underlying erythema and tenderness without mucosal involvement. Labs were notable for a creatinine of 3.3 mg/dL, with no prior history of renal disease, and uric acid of 12.7 mg/dL. He was admitted to the intensive care unit given >80% of body surface area involvement and acute renal failure. Despite aggressive fluid resuscitation, renal function did not improve, and creatinine peaked at 4.61 mg/dL. Urine microscopy showed diffuse polymorphic uric acid crystals, consistent with uric acid crystal-induced nephropathy. He was started on rasburicase, urinary alkalinization, and fluids. His renal function improved dramatically; urine output, uric acid, and electrolytes normalized. He was discharged on topical clobetasol and leflunomide and started on secukinumab with little to no skin involvement. CONCLUSION: This case presents the rare complication of crystal-induced nephropathy in a patient with erythrodermic psoriasis. Uric acid crystal nephropathy is well described in diseases with rapid cell turnover such as tumor lysis syndrome. It is thought that rapid keratinocyte differentiation and inflammatory infiltration of psoriatic lesions produced life-threatening electrolyte abnormalities similar to tumor lysis syndrome. Early recognition of this rare complication is critical, and aggressive fluid resuscitation, urine alkalinization, and uric acid lowering agents should be administered immediately.
format Online
Article
Text
id pubmed-6458895
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-64588952019-04-28 Erythrodermic Psoriasis Causing Uric Acid Crystal Nephropathy Ellis, John Lew, Jeffrey Brahmbhatt, Sumir Gordon, Sarah Denunzio, Troy Case Rep Med Case Report BACKGROUND: Erythrodermic psoriasis is a rare and severe variant of psoriasis. It is characterized by widespread skin erythema, scaling, pustules, or exfoliation of more than 75% of the body's surface area. This condition has life-threatening complications to include hemodynamic, metabolic, immunologic, and thermoregulatory disturbances. One metabolic complication, hyperuricemia, occurs from rapid keratinocyte differentiation and infiltration of inflammatory cells into psoriatic lesions. Although renal injury caused by shunting of blood to the skin has been reported, there are no reports of erythrodermic psoriasis causing crystal-induced nephropathy. We present a case of erythrodermic psoriasis and hyperuricemia complicated by uric acid crystal nephropathy. CASE PRESENTATION: A 57-year-old male with long-standing psoriatic arthritis presented with diffuse scaling of his skin. He was being treated with adalimumab, leflunomide, and topical clobetasol, but had recently stopped taking his medications. Physical exam revealed yellow scaling covering his entire body with underlying erythema and tenderness without mucosal involvement. Labs were notable for a creatinine of 3.3 mg/dL, with no prior history of renal disease, and uric acid of 12.7 mg/dL. He was admitted to the intensive care unit given >80% of body surface area involvement and acute renal failure. Despite aggressive fluid resuscitation, renal function did not improve, and creatinine peaked at 4.61 mg/dL. Urine microscopy showed diffuse polymorphic uric acid crystals, consistent with uric acid crystal-induced nephropathy. He was started on rasburicase, urinary alkalinization, and fluids. His renal function improved dramatically; urine output, uric acid, and electrolytes normalized. He was discharged on topical clobetasol and leflunomide and started on secukinumab with little to no skin involvement. CONCLUSION: This case presents the rare complication of crystal-induced nephropathy in a patient with erythrodermic psoriasis. Uric acid crystal nephropathy is well described in diseases with rapid cell turnover such as tumor lysis syndrome. It is thought that rapid keratinocyte differentiation and inflammatory infiltration of psoriatic lesions produced life-threatening electrolyte abnormalities similar to tumor lysis syndrome. Early recognition of this rare complication is critical, and aggressive fluid resuscitation, urine alkalinization, and uric acid lowering agents should be administered immediately. Hindawi 2019-03-28 /pmc/articles/PMC6458895/ /pubmed/31031815 http://dx.doi.org/10.1155/2019/8165808 Text en Copyright © 2019 John Ellis et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Ellis, John
Lew, Jeffrey
Brahmbhatt, Sumir
Gordon, Sarah
Denunzio, Troy
Erythrodermic Psoriasis Causing Uric Acid Crystal Nephropathy
title Erythrodermic Psoriasis Causing Uric Acid Crystal Nephropathy
title_full Erythrodermic Psoriasis Causing Uric Acid Crystal Nephropathy
title_fullStr Erythrodermic Psoriasis Causing Uric Acid Crystal Nephropathy
title_full_unstemmed Erythrodermic Psoriasis Causing Uric Acid Crystal Nephropathy
title_short Erythrodermic Psoriasis Causing Uric Acid Crystal Nephropathy
title_sort erythrodermic psoriasis causing uric acid crystal nephropathy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458895/
https://www.ncbi.nlm.nih.gov/pubmed/31031815
http://dx.doi.org/10.1155/2019/8165808
work_keys_str_mv AT ellisjohn erythrodermicpsoriasiscausinguricacidcrystalnephropathy
AT lewjeffrey erythrodermicpsoriasiscausinguricacidcrystalnephropathy
AT brahmbhattsumir erythrodermicpsoriasiscausinguricacidcrystalnephropathy
AT gordonsarah erythrodermicpsoriasiscausinguricacidcrystalnephropathy
AT denunziotroy erythrodermicpsoriasiscausinguricacidcrystalnephropathy